الفهرس يوجد فقط 14 صفحة متاحة للعرض العام
 |  | from | 123 |  |  |
| | | from | 123 | | |
المستخلص
Efforts to develop pharmacological treatments for obesity have increased tremendously in the last decade, spurred by the increase of obesity prevalence and its recognition as a chronic disease with severe consequences and complications.
More efficient drugs are still required to combat the obesity epidemic. Gut peptides have received growing attention for their ability to regulate many gastro intestinal functions, particularly those related to food intake and digestive motility. In contrast to the current medications that affects systems relatively indiscriminately, the use of gut hormones as therapeutic agents would have the advantage of targeting only the relevant appetite control systems. It seems likely that permanent weight loss will require continuous treatment throughout the life of a patient, or at least for extended periods of time.
Our study showed that ghrelin hormone level is markedly elevated after over night fasting which shows that ghrelin hormone is an orixogenic hormone and stimulates feeding behavior. Thus, ghrelin itself may be useful orexigenic agent for the treatment of disorders accompanied by chronic malnutrition due to decreased food intake such as anorexia nervosa. However, it should be noted, that appetite is regulated by numerous factors that may interact with and compensate for each other. Therefore the effectiveness of such approach has to be directly shown in clinical studies. Further research is required to investigate whether ghrelin antagonists/agonists might be viable anti obesity/malnutrition-treating drugs that can be used in wide clinical practice.